EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Multi-Laboratory, Multi-Platform Analysis of the Multi-Attribute Method

Joshua Shipman iD, Mercy Oyugi, Tim Andres Marzan, Ilan Geerlof-Vidavsky, Douglas Kirkpatrick, Hongbin Zhu, Milani Rasangika, Sarah Rogstad iD

Pharmaceuticals · 25.10.2025 · 18 (11) · 1613

DOI: 10.3390/ph18111613 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 25.10.2025. Verfasst von Joshua Shipman und 7 weiteren Autor:innen. Beteiligte Einrichtung: Office of Pharmaceutical Quality Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Saint Louis, MO 63110, USA. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The multi-attribute method (MAM) has found diverse use in the analytical characterization of therapeutic protein products during their development and production. As the MAM matures it has the potential to enter quality control (QC) laboratories, consolidating and replacing many less informative chromatographic techniques; however, this requires an appropriate risk assessment and understanding of method capability.

Methods

A validated MAM approach was used to quantify product quality attributes (PQAs) using three different mass spectrometers across two laboratories; the results were compared to conventional hydrophilic interaction chromatography–fluorescence detection (HILIC-FLD) and cation exchange chromatography–ultraviolet (CEX-UV) techniques.

Results

Stressed, long-term, and accelerated stability studies were performed, and their effects on glycosylation, deamidation, oxidation and N- and C-termini were quantified.

Conclusions

Overall, the inter-instrument inter-laboratory data provided here showed important considerations for transferring methods between laboratories and establishing the correlation between the MAM and conventional data, elements which are necessary to transition the MAM to the QC environment and ultimately achieving the goal of replacing orthogonal QC methods.

Schlagwörter

Stichwörter der Autor:innen

mass spectrometrymonoclonal antibodiesmulti-attribute methodquality control

Autor:innen und Institutionen

  • Office of Pharmaceutical Quality Research, Center for Drug Evaluation and Research, US Food and Drug Administration, Saint Louis, MO 63110, USA.
  • Office of Product Quality Assessment, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD 20903, USA.
  • BridgeBio, Palo Alto, CA 94304, USA.
  • Office of Science and Engineering Laboratories, Center for Devices and Radiological Health, US Food and Drug Administration, Silver Spring, MD 20903, USA.

ORCID-Profile: Joshua Shipman, Sarah Rogstad

Zitieren

APA

Shipman, J., Oyugi, M., Marzan, T. A., Geerlof-Vidavsky, I., Kirkpatrick, D., Zhu, H., Rasangika, M., & Rogstad, S. (2025). A Multi-Laboratory, Multi-Platform Analysis of the Multi-Attribute Method. Pharmaceuticals, 18(11), 1613. https://doi.org/10.3390/ph18111613

Vancouver

Shipman J, Oyugi M, Marzan TA, Geerlof-Vidavsky I, Kirkpatrick D, Zhu H, et al. A Multi-Laboratory, Multi-Platform Analysis of the Multi-Attribute Method. Pharmaceuticals. 2025;18(11):1613. doi:10.3390/ph18111613

BibTeX
@article{Shipman2025,
  author = {Shipman, Joshua and Oyugi, Mercy and Marzan, Tim Andres and Geerlof-Vidavsky, Ilan and Kirkpatrick, Douglas and Zhu, Hongbin and Rasangika, Milani and Rogstad, Sarah},
  title = {A Multi-Laboratory, Multi-Platform Analysis of the Multi-Attribute Method},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {11},
  pages = {1613},
  doi = {10.3390/ph18111613}
}
Kostenlos starten →